References
- Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–20.
- Bramer SL, Forbes WP. (1999). Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet 37:13–23.
- Dressman JB, Amidon GL, Reppas C, Shah VP. (1998). Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15:11–22.
- Food and Drug Administration (FDA). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. 2002.
- Gotoh F, Tohgi H, Hirai S, et al. (2000). Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Celebrovasc Dis 9:147–57.
- Itoh T, Higuchi T, Gardner CR, Caldwell L. (1986). Effect of particle size and food on gastric residence time of non-disintegrating solids in beagle dogs. J Pharm Pharmacol 38:801–8.
- Jinno J, Kamada N, Miyake M, et al. (2006). Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 111:56–64.
- Kamada N, Yamada K, Odomi M, et al. (2011). Sex differences in pharmacokinetics of cilostazol in rats. Xenobiotica 41:903–13.
- Kaniwa N, Aoyagi N, Ogata H, Ejima A. (1988). Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates. J Pharmacobiodyn 11:563–70.
- Kimura Y, Tani T, Kanbe T, Watanabe K. (1985). Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35:1144–9.
- Kovacević I, Parojcić J, Homsek I, et al. (2009). Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 6:40–7.
- Miyake M, Toguchi H, Nishibayashi T, et al. (2013). Establishment of novel prediction system of intestinal absorption in humans using human intestinal tissues. J Pharm Sci 102:2564–71.
- Miyake M, Nakai D. (2017). Effect of proinflammatory cytokine IL-6 on efflux transport of rebamipide in Caco-2 cells. Xenobiotica 47:821–4.
- Miyake M, Koga T, Kondo S, et al. (2017). Prediction of drug intestinal absorption in human using the Ussing chamber system: a comparison of intestinal tissues from animals and humans. Eur J Pharm Sci 96:373–80.
- Parr AF, Sandefer EP, Wissel P, et al. (1999). Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and beagle dog. Pharm Res 16:266–71.
- Porter CJ, Trevaskis NL, Charman WN. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6:231–48.
- Singh BN. (1999). Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213–55.
- Stappaerts J, Wuyts B, Tack J, et al. (2014). Human and simulated intestinal fluids as solvent systems to explore food effects on intestinal solubility and permeability. Eur J Pharm Sci 63:178–86.
- Sunesen VH, Vedelsdal R, Kristensen HG, et al. (2005). Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci 24:297–303.
- Willis BA, Zhang W, Ayan-Oshodi M, et al. (2012). Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. J Clin Pharmacol 52:904–13.
- Xu CH, Cheng G, Liu Y, et al. (2012). Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. Biopharm Drug Dispos 33:30–8.